RHYTHM BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.084 AUD | -7.69% |
|
-9.68% | -37.78% |
| Apr. 24 | Rhythm Biosciences Appoints CEO; Shares Down 3% | MT |
| Mar. 21 | Rhythm Biosciences Receives AU$2.5 Million Under Rights Issue; Shares Up 3% | MT |
Valuation
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 20.65 | 18.13 | 7.959 | 178.9 | 246.2 | 90.11 |
| Enterprise Value (EV) 1 | 12.83 | 13.36 | 6.159 | 176.6 | 238.8 | 86.03 |
| P/E ratio | -9.11 x | -7.11 x | -1.98 x | -24.8 x | -27.4 x | -10.8 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 17,647,412 x | 79,591,490 x | 161,407,158 x | 101,422,775 x | 29,108,385 x |
| EV / Revenue | - | 13,002,383 x | 61,586,280 x | 159,356,295 x | 98,363,837 x | 27,789,011 x |
| EV / EBITDA | -8.03 x | -5.1 x | -1.55 x | -27.1 x | -27.4 x | -10.3 x |
| EV / FCF | -10.5 x | -6.1 x | -4.46 x | -59.4 x | -72.7 x | -20.9 x |
| FCF Yield | -9.56% | -16.4% | -22.4% | -1.68% | -1.37% | -4.79% |
| Price to Book | 2.49 x | 3.1 x | 4.32 x | 105 x | 33.4 x | 15.3 x |
| Nbr of stocks (in thousands) | 100,750 | 100,750 | 100,750 | 202,171 | 214,082 | 219,793 |
| Reference price 2 | 0.2050 | 0.1800 | 0.0790 | 0.8850 | 1.150 | 0.4100 |
| Announcement Date | 8/31/18 | 8/29/19 | 8/31/20 | 8/31/21 | 8/29/22 | 8/31/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | 1.028 | 0.1 | 1.109 | 2.427 | 3.096 |
| EBITDA 1 | -1.597 | -2.622 | -3.98 | -6.518 | -8.724 | -8.345 |
| EBIT 1 | -1.629 | -2.687 | -4.061 | -6.625 | -8.818 | -8.446 |
| Operating Margin | - | -261.5% | -4,061.45% | -597.65% | -363.29% | -272.81% |
| Earnings before Tax (EBT) 1 | -1.753 | -2.546 | -4.023 | -6.612 | -8.794 | -8.218 |
| Net income 1 | -1.753 | -2.546 | -4.023 | -6.612 | -8.794 | -8.218 |
| Net margin | - | -247.77% | -4,022.98% | -596.49% | -362.26% | -265.44% |
| EPS 2 | -0.0225 | -0.0253 | -0.0399 | -0.0357 | -0.0419 | -0.0379 |
| Free Cash Flow 1 | -1.226 | -2.192 | -1.38 | -2.972 | -3.283 | -4.124 |
| FCF margin | - | -213.3% | -1,380.36% | -268.07% | -135.24% | -133.23% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/31/18 | 8/29/19 | 8/31/20 | 8/31/21 | 8/29/22 | 8/31/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 7.83 | 4.77 | 1.8 | 2.27 | 7.43 | 4.08 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -1.23 | -2.19 | -1.38 | -2.97 | -3.28 | -4.12 |
| ROE (net income / shareholders' equity) | -36.1% | -36% | -105% | -373% | -194% | -124% |
| ROA (Net income/ Total Assets) | -20.4% | -22.9% | -57.2% | -145% | -95.8% | -65.4% |
| Assets 1 | 8.611 | 11.13 | 7.033 | 4.564 | 9.18 | 12.56 |
| Book Value Per Share 2 | 0.0800 | 0.0600 | 0.0200 | 0.0100 | 0.0300 | 0.0300 |
| Cash Flow per Share 2 | 0.0800 | 0.0500 | 0.0200 | 0.0100 | 0.0400 | 0.0200 |
| Capex 1 | 0.01 | 0.11 | 0.05 | 0.07 | 0.03 | 0.1 |
| Capex / Sales | - | 10.73% | 45.54% | 6.16% | 1.11% | 3.2% |
| Announcement Date | 8/31/18 | 8/29/19 | 8/31/20 | 8/31/21 | 8/29/22 | 8/31/23 |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -37.78% | 13.47M | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -37.00% | 391M | |
| -46.94% | 377M |
- Stock Market
- Equities
- RHY Stock
- Financials Rhythm Biosciences Limited
